
The average zzso pancreatic cancer patient undergoing zzso therapy is frequently overweight rather than zzso and this can confound conventional measures used for risk zzso The aim of this study was to evaluate if weight and body zzso specifically zzso assessed from diagnostic zzso zzso zzso scans, is of zzso value in patients with pancreatic zzso The nature and extent of tissue loss over subsequent months was also zzso 

A total of 111 patients entering a zzso therapy program, who had CT images and had undergone nutritional zzso were zzso In patients for whom follow-up scans were available zzso zzso zzso zzso changes in body composition were studied at a mean of 230 zzso 62 and 95 zzso 60 days prior to zzso 

zzso patients zzso were zzso 44 zzso were zzso and 18 zzso were zzso zzso or zzso years zzso ratio, zzso zzso confidence zzso zzso P zzso zzso and zzso zzso zzso ratio, zzso zzso confidence zzso zzso P zzso zzso were identified as independent zzso of survival on zzso zzso zzso analysis revealed that total zzso mass index decreased from zzso zzso zzso zzso to zzso zzso zzso zzso zzso zzso zzso and total fat mass index decreased from zzso zzso zzso to zzso zzso zzso zzso zzso over 135 zzso 

zzso in zzso patients with advanced pancreatic cancer is an zzso condition but can be identified using CT zzso This condition is an independent adverse zzso indicator that should be considered for zzso of patients' entering clinical trials, systemic therapy, or support care zzso 

